Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07507435 · ClinicalTrials.gov registry record · NA
Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults
A NA study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Not yet
- Registry status
- NA
- Development phase
- 480
- Enrollment target
NCT07507435: Clinical Trial NA study, sponsored by Seattle Institute for Biomedical and Clinical Research.
NCT07507435 is a NA study that has not yet begun recruiting, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 480 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07507435, a NA study, has not yet begun recruiting, sponsored by Seattle Institute for Biomedical and Clinical Research.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 480 participants
- Enrollment target
Study Summary
People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality. Several modifiable factors increase this risk, including active smoking, inadequate receipt of respiratory vaccinations, and inappropriate or prolonged use of inhaled corticosteroids (ICS) or proton-pump inhibitors (PPIs). OPTIMIZE Lung-HIV is a multicenter, patient-level randomized controlled hybrid Type 1 effectiveness-implementation trial evaluating whether a proactive, pharmacist-led E-consult intervention can improve evidence-based pulmonary pharmacotherapy for PWH. Pharmacists will review electronic health records, generate tailored recommendations, and pre-enter orders related to smoking cessation pharmacotherapy, vaccinations, and deprescribing of ICS or PPIs. Providers may enact or modify recommendations as clinically appropriate. The trial will assess the proportion of recommendations enacted within 3 months (primary outcome) and at 12 months (maintenance) and will use mixed methods guided by CFIR and RE-AIM to evaluate adoption, feasibility, acceptability, and implementation barriers and facilitators.
Primary Outcome
Numerator = Number of recommended medication changes ordered (by provider) and filled (by patient). Denominator = Number of medication changes recommended by pharmacist E-consult. Outcomes extracted by data query from VA Electronic Health Record (EHR) pharmacy data.
Interventions
- OTHER E-consult
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2026-08 |
| Est. Completion | 2029-09 |
| Phase | NA |
What is known before NCT07507435 opens enrollment
NCT07507435 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 1 intervention - of which E-consult is the first listed.
NCT07507435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07507435 about?
NCT07507435 is a clinical study titled "Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults". People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality. Several modifiable fact...
What is the current status of trial NCT07507435?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 480 participants. The study started on 2026-08. Estimated completion is 2029-09.
What interventions are being tested in trial NCT07507435?
The interventions under investigation include: E-consult (OTHER).
Who is sponsoring clinical trial NCT07507435?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07507435's enrollment target sits among peer trials
480 216th of 2000 higher than 1,783 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia